Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.52%
+3.51%
+210.53%
+1.67%
NVS
Novartis AG
$131.55
Login to see Novartis AG (NVS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Expands stock buyback program
Outperform the market
Risk Analysis
Downgraded on weak valued
Chart
$127.7 (+3.01%)
$118.95 (+10.59%)
$109.58 (+20.05%)
$114.32 (+15.07%)
NVS has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
NVS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Downgraded on weak valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Expands stock buyback program
Future
Future
Earnings are forecast to grow
Outperform the market
NVS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
NVS Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayNVS Earnings
The TTM reflects 12-month period, providing review of NVS financial performance.
The company financial health has moderately improved over the past year
Financial Score
PFE
26.25
-0.66%
AZN
85.93
+0.44%
MRK
87.57
-1.42%
SNY
49.20
-1.04%
LLY
843.92
-0.20%
What is NVS current stock price?
What are NVS stock strengths?
What risks are associated with NVS stock?
When is NVS next earnings report?
What is NVS market cap and volume?
What is NVS's current Stock IQ?
Should I buy NVS stock right now?
Is NVS a Strong Buy right now?
What does a 'Strong Buy' rating mean for NVS?
What does a 'Strong Sell' rating mean for NVS?
What factors influence NVS's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.52%
+3.51%
+210.53%
+1.67%
NVS
Novartis AG
Current Price
$131.55
Stock Insights
Strengths
Earnings are forecast to grow
Expands stock buyback program
Outperform the market
Risk Analysis
Downgraded on weak valued
Linked to NVS
PFE
26.25
-0.66%
AZN
85.93
+0.44%
MRK
87.57
-1.42%
SNY
49.20
-1.04%
LLY
843.92
-0.20%
Login to unlock Novartis AG (NVS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$127.7 (+3.01%)
$118.95 (+10.59%)
$109.58 (+20.05%)
$114.32 (+15.07%)
NVS Analysts Opinion
NVS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Downgraded on weak valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Expands stock buyback program
Future
Future
Earnings are forecast to grow
Outperform the market
NVS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
NVS Street view is extremely bullish and have positive views on the near-term outlook
NVS has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayNVS Earnings
The TTM data reflects the most recent 12-month period, providing overview of NVS financial performance.
NVS Financial Health
The company financial health has moderately improved over the past year
Financial Score
NVS Latest Analysis
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Mon Oct 6, 2025
3 Reasons Growth Investors Will Love Novartis (NVS). Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Mon Oct 6, 2025
NVS Named Top 10 SAFE International Dividend Stock. Novartis (Symbol: NVS) has been named to the Dividend Channel International S.A.F.E. 10 list signifying an international stock with above-average DividendRank statistics including a strong 3.0% yield as well as a superb track record of at least five years of dividend
Mon Oct 6, 2025
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance.
Fri Oct 3, 2025
Novartis AG (NVS) Hit a 52 Week High Can the Run Continue?. Novartis (NVS) is at a 52-week high but can investors hope for more gains in the future? We take a look at the companys fundamentals for clues.
Thu Oct 2, 2025
FDA Approves Novartis Rhapsido As First BTKi Oral Therapy For Chronic Spontaneous Urticaria . (RTTNews) - Novartis (NVS) announced that the United States Food and Drug Administration has approved Rhapsido (remibrutinib) as an oral treatment for adults with chronic spontaneous urticaria or CSU who continue to experience symptoms despite H1 antihistamine therapy. Taken twice daily
Wed Oct 1, 2025
Atrial Fibrillation Clinical Trials & Pipeline Overview: Insights into 12 Leading Companies and 15 Novel Treatments | DelveInsight. Atrial Fibrillation Clinical Trials &. Pipeline Overview: Insights into 12 Leading Companies and 15 Novel Treatments |. DelveInsightAtrial Fibrillation the most common cardiac arrhythmia poses serious risks such as stroke and heart failure. With its prevalence rising sharply among older adults the aging global population is expected to be a major driver of ma
Tue Sep 30, 2025
Novartis wins FDA approval of BTK inhibitor remibrutinib for urticaria.
Tue Sep 30, 2025
Pharmas Direct-To-Patient Wave Hits Novartis Next. The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster United States manufacturing ease patient costs and .The trade group emphasized that these efforts reflect the biopharmaceutical industry’.s long-term commitment to American patients and workers.PhRMA member companies to make what the organization described as historic investments in United States-based manufacturing and infrastructure.Also Read
Mon Sep 29, 2025
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates. Usman Azam M.D. is appointed President and Chief Executive Officer of Cue Biopharma effective September 29 2025Daniel Passeri Chief Executive Officer of Cue Biopharma transitions to Strategic Advisor to provide ongoing support to the Company Cue Biopharma prioritizes autoimmune disease for next stage of growth with focus on advancing first-in-class
Mon Sep 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings